Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study

202131 citationsJournal Articlegold Open Access

Authors

Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least 8 months.

Good health and well-being

Published in: BMC Medicine

Volume 19, Issue 1, pp. 270-270

Field-Weighted Citation Impact: 1.76